TLR3 and breast carcinoma: In 2022, Yuan Chunhui and others constructed engineered exosomes-HELA-Exos, combining Toll-like receptor 3(TLR3) agonists and immunogenic cell death(ICD) inducers, which can activate dendritic cells in situ and specifically induce ICD in breast cancer cells.